Cargando…

Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort

BACKGROUND: Tumor mutation burden (TMB) may predict the immune checkpoint inhibitor (ICI) response. The TMB calculation includes all nonsynonymous somatic mutations, but not all mutations are favorable, and the efficiency of TMB is attenuated by including adverse mutations. Moreover, no universal cu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yuan, Chen, Zuhua, Wu, Long, Tao, Weiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210182/ https://www.ncbi.nlm.nih.gov/pubmed/32395490 http://dx.doi.org/10.21037/atm.2020.03.163

Ejemplares similares

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
por: Pham, Timothy V., et al.
Publicado: (2020)

Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden
por: Yuan, Hong, et al.
Publicado: (2021)

MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan‐cancer
por: Yang, Yue, et al.
Publicado: (2020)

Pan-cancer analysis of the effect of biopsy site on tumor mutational burden observations
por: Papillon-Cavanagh, Simon, et al.
Publicado: (2021)

Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions
por: Stenzinger, Albrecht, et al.
Publicado: (2019)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
por: Wang, Peipei, et al.
Publicado: (2021)

Racial disparities in patient survival and tumor mutation burden, and the association between tumor mutation burden and cancer incidence rate
por: Zhang, Wensheng, et al.
Publicado: (2017)

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting
por: Joshi, Rushikesh S., et al.
Publicado: (2022)

Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
por: Wood, Mary A., et al.
Publicado: (2020)

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
por: Chan, T A, et al.
Publicado: (2019)

MHC-I genotype and tumor mutational burden predict response to immunotherapy
por: Goodman, Aaron M., et al.
Publicado: (2020)

Tumor mutational burden as a predictor of immunotherapy response in breast cancer
por: O’Meara, Tess A., et al.
Publicado: (2021)

Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis
por: Wu, Rui-Yan, et al.
Publicado: (2023)

Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing
por: Wang, Hai-Yun, et al.
Publicado: (2021)

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
por: Cristescu, Razvan, et al.
Publicado: (2022)

Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer
por: Kim, Jinchul, et al.
Publicado: (2020)

Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide‐induced high tumor mutational burden
por: Cao, Yanshuo, et al.
Publicado: (2020)

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors
por: Kim, Hana, et al.
Publicado: (2021)

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy
por: Aggarwal, Charu, et al.
Publicado: (2023)

Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds
por: Alsaihati, Burair A., et al.
Publicado: (2021)

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2021)

Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors
por: Shao, Changxia, et al.
Publicado: (2020)

Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival
por: Gao, Yanmei, et al.
Publicado: (2020)

Tumor mutation burden and recurrent tumors in hereditary lung cancer
por: Hsu, Yi‐Chiung, et al.
Publicado: (2019)

Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort
por: Li, Chunbo, et al.
Publicado: (2022)

Cellular heterogeneity map of diverse immune and stromal phenotypes within breast tumor microenvironment
por: Li, Yuan, et al.
Publicado: (2020)

Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
por: Alghamri, Mahmoud S, et al.
Publicado: (2020)

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
por: Shemesh, Colby S., et al.
Publicado: (2020)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
por: Rose Brannon, A., et al.
Publicado: (2021)

Tumor mutation burden: from comprehensive mutational screening to the clinic
por: Galuppini, Francesca, et al.
Publicado: (2019)

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
por: Thomas, Alexandra, et al.
Publicado: (2018)

Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review
por: Zhu, Peng-Fei, et al.
Publicado: (2021)

Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types
por: Sinha, Neelam, et al.
Publicado: (2022)

SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy
por: Zheng, Xiaobin, et al.
Publicado: (2023)

Combination of Tumor Mutational Burden and Specific Gene Mutations Stratifies Outcome to Immunotherapy Across Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
por: Peng, Ying-Peng, et al.
Publicado: (2021)

EPCT-13. SINGLE INSTITUTION RETROSPECTIVE ANALYSIS OF TUMOR MUTATIONAL BURDEN AND SURVIVAL IN PEDIATRIC BRAIN TUMORS
por: Parisi, Rose, et al.
Publicado: (2021)

Emerging Roles of the Mitogen and Stress Activated Kinases MSK1 and MSK2
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2016)

Association of Genomic Instability Score, Tumor Mutational Burden, and Tumor-Infiltrating Lymphocytes as Biomarkers in Uterine Serous Carcinoma
por: Bloom, Elizabeth A., et al.
Publicado: (2023)

Co-mutations in tumor immune microenvironment and immunotherapy
por: Ma, Ling, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i5jdrvf4p9g8euh8867r3vks4n